---
schema_version: "secwatch.filing_event.v1"
accession: "0001005286-23-000027"
form_type: "8-K"
ticker: "LFCR"
cik: "0001005286"
company_name: "LIFECORE BIOMEDICAL, INC. DE"
filed_at: "2023-01-11T23:59:59+00:00"
generated_at: "2026-06-20T16:21:34.202764+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lifecore Biomedical receives Nasdaq notice for delayed Q2 FY2023 10-Q filing

## Summary
- Nasdaq notified Lifecore on Jan 11, 2023 of non-compliance with Listing Rule 5250(c)(1) due to late 10-Q.
- Company has 60 days (until Mar 12, 2023) to submit a plan to regain compliance.
- If plan accepted, Nasdaq may grant up to 180 days from original due date (until Jul 5, 2023) to file.
- No immediate impact on listing or trading of common stock on Nasdaq Global Select Market.
- Lifecore states it is working diligently to complete and file the 10-Q as promptly as possible.

## SEC filing metadata
- accession: 0001005286-23-000027
- form_type: 8-K
- ticker: LFCR
- cik: 0001005286
- company_name: LIFECORE BIOMEDICAL, INC. DE
- filed_at: 2023-01-11T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1005286/000100528623000027/0001005286-23-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1005286/000100528623000027/lndc-20230111.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001005286-23-000027
- JSON: https://secwatch.observer/filing/0001005286-23-000027.json
- Plain text: https://secwatch.observer/filing/0001005286-23-000027.txt

## Key facts
- Listing & Compliance Notices
  LIFECORE BIOMEDICAL, INC. DE received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: late filing
  - Rules: 5250(c)(1)
  source text: January 11, 2023, Lifecore Biomedical, Inc., a Delaware corporation (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the period ended November 27, 2022 (the “Form 10-Q”) with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”). The notification letter has no immediat
  evidence_url: https://www.sec.gov/Archives/edgar/data/1005286/000100528623000027/0001005286-23-000027-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.